Patents by Inventor Sarvajit Chakravarty

Sarvajit Chakravarty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050171123
    Abstract: The invention is directed to methods to inhibit TGF-? and/or p38-? kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar? is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    Type: Application
    Filed: February 7, 2005
    Publication date: August 4, 2005
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John Perumattam, George Schreiner, David Liu, John Lewicki
  • Patent number: 6903096
    Abstract: The invention is directed to methods to inhibit TGF-? and/or p38-? kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar? is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: June 7, 2005
    Assignee: Scios, Inc.
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Publication number: 20050096333
    Abstract: Quinazoline derivatives have the formula: or the pharmaceutically acceptable salts thereof; wherein each of Z5, Z6, Z7 and Z8 is N or CH and wherein one or two Z5, Z6, Z7 and Z8 are N and wherein two adjacent Z positions cannot be N; wherein m and n are each independently 0-3; wherein R1 is independently OH, SH, NH2, OR, SR, NHR, halo or R-halide; wherein two adjacent R1 groups may be joined to form an aliphatic hetero cycle ring of 5-6 members; wherein R2 is independently R, halo, R-halide, OR-halide, NH2, CONH2 or CONHR; wherein R is optionally substituted C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl, or aryl C1-C12 alkyl, containing 0-4 heteroatoms in place of a carbon in the carbon backbone, where the optional substituents are ?O, ?N, or OH; and wherein R3 is H or CH3. Such compounds are useful in pharmaceutical compositions and methods of treating conditions characterized by enhanced TGF? activity.
    Type: Application
    Filed: September 30, 2004
    Publication date: May 5, 2005
    Inventors: Sundeep Dugar, Sarvajit Chakravarty, Alison Murphy, Glenn McEnroe, Aurelia Conte, John Perumattam
  • Patent number: 6867209
    Abstract: The invention is directed to methods to inhibit p38-? kinase using compounds of the formula and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein represents a single or double bond; one Z2 is CA or CR8A and the other is CR1, CR12, NR6 or N wherein each R1, R6 and R8 is independently hydrogen or noninterfering substituent; A is —Wi—COXjY wherein Y is COR2 or an isostere thereof and R2 is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6 ?, and each of i and j is independently 0 or 1; as Z3 is NR7 or O; each R3 is independently a noninterfering substituent; n is 0-3; each of L1 and L2 is a linker; each R4 is independently a noninterfering substituent; m is 0-4; Z1 is CR5 or N wherein R5 is hydrogen or a noninterfering substituent; each of 1 and k is an integer from 0-2 wherein the sum of 1 and k is 0-3; Ar is an aryl group substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring
    Type: Grant
    Filed: May 19, 2000
    Date of Patent: March 15, 2005
    Assignee: Scios, Inc.
    Inventors: Babu J. Mavunkel, Sarvajit Chakravarty, John J. Perumattam, Sundeep Dugar, Qing Lu, Xi Liang
  • Patent number: 6864260
    Abstract: The invention is directed to methods to inhibit p38-? kinase using compounds which contain a phenyl group linked through a piperazine ring to a substituted indole.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: March 8, 2005
    Assignee: Scios, Inc.
    Inventors: Babu J. Mavunkel, Sarvajit Chakravarty, John J. Perumattam, Sundeep Dugar, Qing Lu, Xi Liang
  • Publication number: 20050004143
    Abstract: Compounds in which a pyrimidine nucleus is bridged at the 5 and 6 position and are further substituted at positions 2 and 4 with substituents comprising aromatic moieties are useful in treating subjects with conditions ameliorated by inhibition of TGF? activity.
    Type: Application
    Filed: March 26, 2004
    Publication date: January 6, 2005
    Inventors: Sundeep Dugar, Sarvajit Chakravarty, Aurelia Conte, Jonathan Axon, Glenn McEnroe, Alison Murphy
  • Publication number: 20040142940
    Abstract: The invention is directed to methods to inhibit p38-&agr; kinase using compounds comprising a phenyl or thienyl coupled through a piperidine or piperazine nucleus to an indole residue wherein the indole residue mandatorily has a substituent on the ring nitrogen which is an amino or substituted amino group.
    Type: Application
    Filed: September 3, 2003
    Publication date: July 22, 2004
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, Qing Lu, Gregory R. Luedtke, Babu J. Mavunkel, John J. Perumattam, Richland W. Tester
  • Publication number: 20040132730
    Abstract: Certain appropriately substituted forms of pyrimidine and triazine are useful in the treatment to conditions associated with enhanced TGF&bgr; activity.
    Type: Application
    Filed: September 10, 2003
    Publication date: July 8, 2004
    Inventors: Jonathan Axon, Sarvajit Chakravarty, Sundeep Dugar, Glenn McEnroe, Alison Murphy
  • Publication number: 20040038856
    Abstract: The invention concerns methods of treating fibroproliferative disorders associated with TGF-&bgr; signaling, by administering non-peptide small molecule inhibitors of TGF-&bgr; specifically binding to the type I TGF-&bgr; receptor (TGF&bgr;-R1). Preferably, the inhibitors are quinazoline derivatives. The invention also concerns methods for reversing the effect of TGF-&bgr;-mediated cell activation on the expression of a gene associated with fibrosis, comprising contacting a cell or tissue in which the expression of such gene is altered as a result of TGF-&bgr;-mediated cell activation, with a non-peptide small molecule inhibitor of TGF-&bgr;, specifically binding a TGF&bgr;-R1 receptor kinase present in the cell or tissue.
    Type: Application
    Filed: May 16, 2003
    Publication date: February 26, 2004
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, Linda S. Higgins, Ann M. Kapoun, David Y. Liu, Andrew A. Protter, George F. Schreiner, Thomas-Toan Tran
  • Publication number: 20030195355
    Abstract: The invention is directed to methods to inhibit p38-&agr; kinase using compounds of the formula 1
    Type: Application
    Filed: May 28, 2002
    Publication date: October 16, 2003
    Inventors: Babu J. Mavunkel, Sarvajit Chakravarty, John J. Perumattam, Sundeep Dugar, Qing Lu, Xi Liang
  • Publication number: 20030162970
    Abstract: The invention is directed to methods to inhibit p38-&agr; kinase using compounds of the formula 1
    Type: Application
    Filed: May 28, 2002
    Publication date: August 28, 2003
    Inventors: Babu J. Mavunkel, Sarvajit Chakravarty, John J. Perumattam, Sundeep Dugar, Qing Lu, Xi Liang
  • Publication number: 20030158417
    Abstract: The invention is directed to methods to inhibit p38-&agr; kinase using compounds of the formula 1
    Type: Application
    Filed: May 14, 2002
    Publication date: August 21, 2003
    Inventors: Babu J. Mavunkel, Sarvajit Chakravarty, John J. Perumattam, Sundeep Dugar, Qing Lu, Xi Liang
  • Publication number: 20030144520
    Abstract: The invention is directed to methods to inhibit p38-&agr; kinase using compounds of the formula 1
    Type: Application
    Filed: May 28, 2002
    Publication date: July 31, 2003
    Inventors: Babu J. Mavunkel, Sarvajit Chakravarty, John J. Perumattam, Sundeep Dugar, Qing Lu, Xi Liang
  • Publication number: 20030069248
    Abstract: The invention is directed to methods to inhibit TGF-&bgr;and/or p38-&agr; kinase using compounds of the formula 1
    Type: Application
    Filed: October 2, 2001
    Publication date: April 10, 2003
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6476031
    Abstract: The invention is directed to methods to inhibit TGF-&bgr; and/or p38-&agr; kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: November 5, 2002
    Assignee: Scios, Inc.
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Publication number: 20020161010
    Abstract: The invention is directed to methods to inhibit TGF-&bgr; and/or p38-&agr; kinase using compounds of the formula 1
    Type: Application
    Filed: October 5, 2001
    Publication date: October 31, 2002
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6410540
    Abstract: The invention is directed to methods to treat conditions mediated by p38-&agr;kinase using compounds of the formula and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein Z is N or CR1, R1 is a noninterfering substituent, each of X1 and X2 is a linker, Ar1 and Ar2 are identical or different, and represent optionally substituted C1-C20 hydrocarbyl residues wherein at least one of Ar1 and Ar2 is an optionally substituted aryl group, with the proviso that when X2 is CH2 or an isostere thereof, X1 is CO or an isostere thereof, and Ar2 is optionally substituted phenyl, Ar1 is other than an optionally substituted indolyl, benzimidazolyl or benzotriazolyl substituent, and wherein said optionally substituted phenyl is not an optionally substituted indolyl, benzimidazolyl, or benzotriazolyl, Y is a noninterfering substituent, wherein n is an integer from 0-4, and wherein m is an integer from 0-4 and 1 is an integer from 0-3.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: June 25, 2002
    Assignee: Scios, Inc.
    Inventors: R. Richard Goehring, Gregory R. Luedtke, Babu J. Mavunkel, Sarvajit Chakravarty, Sundeep Dugar, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6277989
    Abstract: The invention is directed to methods to inhibit TGF-&bgr; and/or p38-&agr; kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: August 21, 2001
    Assignee: Scios, Inc.
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6184226
    Abstract: The invention describes compounds of the formula and the pharmaceutically acceptable salts thereof and the pharmaceutically acceptable salts thereof wherein each R2 is independently a noninterfering substituent; m is an integer of 0-4; Z is CH or N; R1 is H, alkyl (1-6C) or arylalkyl optionally substituted on the aryl group with 1-3 substituents independently selected from alkyl (1-6C), halo, OR, NR2, SR, —OOCR, —NROCR, RCO, —COOR, —CONR2, —SO2NR2, CN, CF3, and NO2, wherein each R is independently H or lower alkyl (1-4C); n is 0, 1 or 2; Ar is phenyl, pyridyl, indolyl, or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR2, SR, —OOCR, —NROCR, RCO, —COOR, —CONR2, SO2NR2, CN, CF3, and NO2, wherein each R is independently H or lower alkyl (1-4C); and R3 is a branched or cyclic alkyl group (5-7C) or is phenyl optionally substituted with 1-2 substi
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: February 6, 2001
    Assignee: Scios Inc.
    Inventors: Sarvajit Chakravarty, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 5543496
    Abstract: Cyclic compounds based on a modified bradykinin sequence are potent bradykinin receptor antagonists. Amino acid substitutions are made at postions 2 and 5 or 6 to facilitate the cyclization of the peptide through covalent bonding of the amino acid side chains.The analogs produced are useful in treating conditions and diseases of a mammal and human in which an excess of bradykinin or related kinins are produced or injected such as by insect bites.
    Type: Grant
    Filed: July 25, 1994
    Date of Patent: August 6, 1996
    Assignee: Scios Nova Inc.
    Inventors: Donald J. Kyle, Sarvajit Chakravarty